Videos

Full video: Experts discuss the overlap between immune-mediated inflammatory diseases in GI and dermatology, emphasizing the importance of cross-specialty care.

In the final segment of this HCPLive Special Report, experts discuss lingering unmet needs in cross-specialty care and look ahead to potential areas for improvement.

In part 2 of their HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, continue their in-depth conversation.

In this HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, discuss the connection between GI and dermatologic care.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Li and Shao discussed the heavy disease burden of type 2 diabetes in the VA population and outlined the VA MOVE! study.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

At SLEEP 2025, Sachdeva discussed the evolving legal implications of AI use in sleep medicine, including clinician liability, informed consent, and responsible integration into care.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

This episode of Lungcast features a discussion on emerging research in lung cancer biomarkers and early detection.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.

At SLEEP 2025, Lillis discussed how wearable data revealed disruptions in sleep consolidation up to 13 weeks postpartum despite total sleep duration nearing pre-pregnancy levels.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

By week 2 postpartum, sleep duration rebounds, but fragmented sleep persists through week 13, Teresa Lillis, PhD, presented at SLEEP 2025.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.